Neurology · AnticonvulsantRegulatory Approvalcommercialnear-term

FDA Grants Approval for Gabapentin ANDA203611 by Actavis Elizabeth

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 6:04:11 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Actavis Elizabeth's generic gabapentin introduces a new competitor in the market, which could significantly impact pricing and market dynamics. Portfolio teams must evaluate the implications for existing gabapentin products and adjust strategies accordingly. Regulatory context from FDA (FDA AP — GABAPENTIN (ORIG)) supports the near-term read. Assessment grounded in 15 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on pricing and market share for gabapentin products. The strongest clinical anchor is ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Anticonvulsant, 4 regulatory and 3 competitive items passed relevance filtering for Gabapentin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves First Generic of Priftin (rifapentine) Tablets (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate). This approval allows Actavis Elizabeth to enter the gabapentin market, increasing competition among generic manufacturers.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GABAPENTIN (ORIG) (FDA). Entity match (gabapentin); Regulatory pathway relevance (nda). The approval signifies compliance with FDA standards but does not indicate any broader regulatory concerns.

Key Risks

Clinical risk from ClinicalTrials.gov (Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products) could weigh on Gabapentin through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Increased competition may lead to price reductions and affect market share for current gabapentin products, potentially impacting revenue streams.
Portfolio teams should assess the impact of this new entrant on pricing and market share for gabapentin products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from Actavis Elizabeth and other competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of Adverse Effects Related to Prescribed Medications in Periodontology Clinic
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pompe Disease Registry Protocol
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves First Generic of Priftin (rifapentine) Tablets
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
Humanexa Signalsmedium relevance
Moderate corpus alignment

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Gabapentin
generic manufacturers

Commercial impact

medium

Increased competition may lead to price reductions and affect market share for current gabapentin products, potentially impacting revenue streams.

Regulatory impact

low

The approval signifies compliance with FDA standards but does not indicate any broader regulatory concerns.

What to watch

Monitor market entry timelines and pricing strategies from Actavis Elizabeth and other competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.